Table 1.

Patient characteristics and results of sequencing analysis

Patient no.SexSmoking statusPrior treatmentGefitinib responseGefitinib treatment daysAnalyzed specimen (state)Nucleic acidActivating mutationT790M mutationT790M (pre-gefitinib samples)
1FNSSE642LN (Fr)RNAΔ2+
2MFSSE368PE (Al)RNAΔ3
3MNSSE116PE (Al)RNAΔ1
4FFSCTE599PE (CL)RNAΔ1NA
5FNSCRTE921LU (Al)RNAΔ1+NA
6FNSNoneE181PE (Al)RNAΔ1+
7FFSCTE346BO (Al)RNAΔ1+
8FNSS→CRTE623LN (Al)RNAL858RNA
9MFSSE915BR (Fr)DNAL858R*
10MFSS→CRTNE69PE (Al)DNAL858R
11FFSNoneE560LU (Fr)RNAL858R*+NA
12FNSCTE239PE (Al)RNAΔ1+
13FNSSE367PE (Al)RNAL858R
14FNSCRTE235LN (Al)RNAΔ1+
  • NOTE: Patients 1, 4, and 13 received gefitinib therapy twice. Pretreatment samples from patients 4, 5, 8, and 11 were not available. Patient 10 was defined as not evaluable according to our definition. However, this patient showed a 46% decrease in carcinoembryonic antigen and a marked reduction in pleural effusion on initial treatment before subsequent progression. Therefore, we regarded this case as eligible for this study.

    Abbreviations: Al, alcohol fixed; BO, bone metastasis; BR, brain metastasis; CL, cell line; CRT, chemoradiotherapy; CT, chemotherapy; del, deletion; E, effective; F, female; Fr, frozen; FS, former smoker; ins, insertion; LN, lymph node; LU, lung tumor; M, male; NA, not available; NE, not evaluable; NS, never smoker; PE, pleural effusion; RT, radiotherapy; S, surgery; Δ1, del E746-A750; Δ2, del L747-P753 insS; Δ3, del L747-A750 insP.

  • * Patients 9 and 11 had another point mutation (L833V in patient 9 and R776H in patient 11).